Business
Posting of 2024 Annual Report and Notice of AGM
Posting of 2024 Annual Report and Notice of AGM.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\nArecor Therapeutics plc\n(\"Arecor\" or the \"Company\")\n \nPosting of Arecor 2024 annual report and notice of AGM\n \nCambridge, UK, 6 May 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 December 2024 and Notice of the Annual General Meeting (\"AGM\") which will be held at the offices of Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ, on Monday 2 June 2025 at 09.30 a.m. (BST).\n \nThe Annual Report and Accounts and notice of AGM are also available to view on, and download from, the Company's website at https://arecor.com/investor-centre/shareholder-information/\n \n-ENDS-\n \nFor more information, please contact:\n \n\n\n\n\nArecor Therapeutics plc\n\n\nwww.arecor.com\n\n\n\n\nDr Sarah Howell, Chief Executive Officer\n\n\nTel: +44 (0) 1223 426060\nEmail: [email protected]\n\n\n\n\nDavid Ellam, Chief Financial Officer\n\n\nTel: +44 (0) 1223 426060\nEmail: [email protected] \n\n\n\n\n\n\n\n\n\n\n\n\nSinger Capital Markets Advisory LLP (NOMAD and Broker)\n\n\n\n\n\n\n\nPhil Davies, Sam Butcher\n\n\nTel: +44 (0) 20 7496 3000\n\n\n\n\n \n\n\n\n\n\n\n\nICR Healthcare\n\n\n\n\n\n\n\nChris Gardner, David Daley, Lindsey Neville\n\n\nTel: +44 (0) 20 3709 5700\nEmail: [email protected] \n\n\n\n\n \n\n\n\n\n\n\n\nNotes to Editors\n \nAbout Arecor\nArecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com\n\n","length":6341,"tagName":"div"}]